page contents

Daiichi Sankyo, MUCAP & Tokyo Tech partner to commence open innovation research on iPS Cell─derived insulin producing cells in Japan

Daiichi Sankyo, Mitsubishi UFJ Capital (MUCAP) and Tokyo Institute of Technology (Tokyo Tech) announced that they will commence open innovation research with the aim of creating insulin producing cells from iPS cells for use in regenerative medicine and cell therapy.

The Kume and Shiraki Lab at the School of Life Science and Technology, Tokyo Tech, has developed a technique to produce pancreatic ß cells (insulin secreting cells in the pancreas) derived from human iPS cells at a high rate. It has been found that this technique enables creation of iPS cell-derived insulin producing cells similar to the body’s own pancreatic …
Technology News

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.